Esophageal GIST: Therapeutic implications of an uncommon presentation of a rare tumor

Diseases of the Esophagus

Volumn 18, Issue 1, 2005, Pages 70-73

  Gouveia, António M ^a,b   Pimenta, A P ^a,b   Lopes, J M ^a,b   Capelinha, A F ^a   Ferreira, S S ^a   Valbuena, C ^a   Oliveira, M C ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Clinical features; Esophagectomy; Esophagus; GIST; Immunohistochemistry; Treatment

Indexed keywords

CD34 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ESOPHAGUS; ESOPHAGUS RESECTION; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; MALE; MITOSIS INDEX; PEROPERATIVE ECHOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SPINDLE CELL; TREATMENT OUTCOME;

ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED;

EID: 17444389307     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2005.00446.x     Document Type: Article

References (25)

1. Fletcher C D M, Berman J J, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs). Definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003; 54: 3-24.
3. DeMatteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
4. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
5. Kindblom L G, Remotti H E, Aldenborg F, Meis-Kindblom J M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-69.
6. Sircar K, Hewlett B R, Huizinga J D, Chorneyko K, Berezin I, Riddell R H. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-89.
7. Sarlomo-Rikala Kovatich A J, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumor that is more specific than CD34. Mod Pathol 1998; 11: 728-34.
8. Lux M L, Rubin B P, Biase T L et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-5.
9. Rubin B P, Fletcher J A, Fletcher C D M. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Sur Pathol 2000; 8: 5-10.
10. Heinrich M C, Corless C L, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
11. Miettinen M, Sarlomo-Rikala M, Sobin L H, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24: 211-22.
12. Gouveia A, Silva P, Costa S, Pimenta A, Oliveira M C, Lopes J M. GIST: The Hospital S. João (Porto) series during the last 13 years (abstract). Hepatogastroenterology 2003; 50: LXIII.
13. Miettinen M, El-Rifai W H L, Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-83.
14. Ng E H, Pollock R E, Munsell M F, Atkinson E N, Romsdahl M M. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77.
15. Roberts P J, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38: S37-S38.
16. Joensuu H, Roberts P J, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
17. van Oosterom A T, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-3.
18. Demetri G D, von Mehren M, Blanke C D et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
19. Heinrich M C, Blanke C D, Druker B J, Corless C L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
20. DeMatteo R P, Heinrich M C, El-Rifai W M, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-77.
21. Blanke C D, von Mehren M, Joensuu H et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI-571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117) (Abstract). Presented at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.
22. Blanke C D, Eisenberg B L, Heinrich M C. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001; 2: 485-91.
23. Kitamura Y, Hirota S, Nishida T. Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci 2003; 94: 315-20.
24. O'Leary T, Berman J J. Gastrointestinal stromal tumors: answers and questions. Hum Pathol 2002; 33: 456-8.
25. Bümming P, Andersson J, Meis-Kindblom J M et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-4.